First Line Gefitinib by FDG-PET Metabolic Response

NCT01510990 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Gefitinib

Sponsor

Asan Medical Center

Collaborators

[object Object]